Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy

作者：Jacob T Brown, J. Bishop, K. Sangkuhl, E. Nurmi, D. Mueller, J. Dinh, A. Gaedigk, T. Klein, K. Caudle, J. McCracken, J. Leon, J. Leeder · 发表于：Clinical pharmacology and therapy · 年份：2019 · DOI：10.1002/cpt.1409 · 被引用次数：163 · 研究领域：Medicine

Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org).